QuatRx Pharmaceuticals

Developing therapeutics for under-served endocrine and metabolic diseases

QuatRx is focused on development of therapeutics for endocrine and metabolic diseases. The company's lead product Osphena, a selective estrogen receptor modulator, was approved by the FDA in 2013 to treat dyspareunia.

Status
Acquired by Shionogi in 2017
Year of Investment
2000
Strategy
Life Sciences
Location
Ann Arbor, Michigan
Frazier Team